



PATENTS  
ASILMR-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Hill et al.  
Application No.: 09/707,730 Confirmation No.: 8812  
Filed: : November 6, 2000  
For: : COMPOUNDS FOR INTRACELLULAR DELIVERY OF  
THERAPEUTIC MOIETIES TO NERVE CELLS  
Group Art Unit : 1647  
Examiner : Sharon L. Turner, Ph.D.

Hon. Commissioner  
for Patents  
c/o P.O. Box 2327  
Arlington, VA 22202

RECEIVED  
AUG 19 2002  
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98,  
applicants hereby make the following documents of record in  
the above identified application: \*

U.S. Patents

5,977,307	11/1999	Friden et al.
5,948,384	09/1999	Filler
5,833,988	11/1998	Friden
5,767,288	06/1998	Stowell et al.
5,614,652	03/1997	Filler et al.
5,563,250	10/1996	Fitzner et al.
5,554,498	09/1996	Filler et al.
5,505,931	04/1996	Pribish
5,502,037	03/1996	Kondratyev

---

\* Applicants reserve the right to challenge the status of any of  
the cited documents as prior art.

### Foreign Patents

WO 97/26275	07/1997	WIPO
WO 97/23608	03/1997	WIPO
WO 97/21732	06/1997	WIPO
WO 95/32738	03/1997	WIPO
WO 95/07092	03/1995	WIPO

### Other Documents

Binkley et al., "RNA Ligands to Human Nerve Growth Factor," *Nucleic Acids Research* vol. 23 no. 16: pp. 3198-3205 (1995).

Fiume et al., "Galactosylated poly(L-lysine) as a Hepatotropic Carrier of 9- $\beta$ -D-arabinofuranosyladenine 5'-monophosphate," *FEBS* 3810 vol. 203 no. 2: pp. 203-206 (July 1986).

Fiume et al., "Drug Targeting in Antiviral Chemotherapy: A Chemically Stable Conjugate of 9- $\beta$ -D-Arabinofuranosyl-Adenine 5'-Monophosphate with Lactosaminated Albumin Accomplishes a Selective Delivery of the Drug to Liver Cells," *Biochemical Pharmacology* vol. 35 no. 6: pp. 967-972 (1986).

Haschke et al., "Preparation and Retrograde Axonal Transport of an Antiviral Drug/Horseradish Peroxidase Conjugate," *Journal of Neurochemistry* vol. 35 no. 6: pp. 1431-1435 (December 1980).

Kramer et al., "Monoclonal Antibody to Human Trk-A: Diagnostic and Therapeutic Potential in Neuroblastoma," *European Journal of Cancer* vol. 33 no. 12: pp. 2090-2091 (October 1997).

Li et al., " $\beta$ -Endorphin Omission Analogs: Dissociation of Immunoreactivity from Other Biological Activities," *Proc. Natl. Acad. Sci. USA* 77( 6): 3211-3214 (1980) (cited on PTO-892 as "Choh et al").

Maliartchouk et al., "Optimal Nerve Growth Factor Trophic Signals Mediated by Synergy of TrkA and p75 Receptor-Specific Ligands," *Journal of Neuroscience* vol. 17 no. 16: pp. 6031-6037 (1997).

Pardridge et al., "Transport of Human Recombinant Brain-Derived Neurotrophic Factor (BDNF) Through the Rat

Blood-Brain Barrier in Vivo Using Vector-Mediated Peptide Drug Delivery," *Pharmaceutical Research* vol. 11 no. 5: pp. 746 (1994).

Ponzetto et al., "Adenine Arabinoside Monophosphate and Acyclovir Monophosphate Coupled to Lactosaminated Albumin Reduce Woodchuck Hepatitis Virus Biremia at Doses Lower than do the Unconjugated Drugs," *Hepatology* vol. 14: pp. 16-24 (1991).

Schwab, M.E., "Ultrastructural Localization of a Nerve Growth Factor-Horseradish Peroxidase (NGF-HRP) Coupling Product after Retrograde Axonal Transport in Adrenergic Neurons," *Brain Research* vol. 130 no. 1: pp. 190-196 (8 July 1977).

Schwab et al., "Labeled Wheat Germ Agglutinin (WGA) as a New, Highly Sensitive Retrograde Tracer in the Rat Brain Hippocampal System," *Brain Research* vol. 152 no. 1: pp. 145-150 (18 August 1978).

Schwab et al., "Selective Retrograde Transsynaptic Transfer of a Protein, Tetanus Toxin, Subsequent to Its Retrograde Axonal Transport," *Journal of Cell Biology* vol. 82 no. 3: pp. 798-810 (September 1979).

Skolnick et al., "From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era," *Trends in Biotechnology* vol. 18 no. 1: pp. 34-39 (2000).

Wilcox et al., "Characterization of Nerve Growth Factor-Dependent Herpes Simplex Virus Latency in Neurons In Vitro," *Journal of Virology* vol. 62 no. 2: pp. 393-399 (February 1988).

Copies of the aforementioned documents, which are listed on the accompanying Form PTO-1449 (submitted in duplicate), are enclosed herewith.

It is respectfully requested that these documents be (1) fully considered by the Patent and Trademark Office during the examination of this application; and (2) printed

on any patent that may issue on this application.  
Applicants request that a copy of Form PTO-1449 (submitted  
in duplicate herewith), as considered and initialed by the  
Examiner, be returned with the next communication.

An early and favorable action is respectfully  
requested.

Respectfully submitted,

9 AUG 2002




Daniel M. Becker  
Reg. No. 38,376  
Attorney for Applicants

I hereby Certify that this  
Correspondence is being  
Deposited with the U.S.  
Postal Service as First  
Class Mail in an Envelope  
Addressed to:  
HON. COMMISSIONER FOR PATENTS,  
Washington, D.C. 20231 on:

FISH & NEAVE  
1251 Avenue of the Americas  
New York, N. Y. 10020  
(650) 617-4000

8/9/02  
Date of Deposit  
Matt Carotto  
8/9/02  
Date of Signature

#10  
 Sheet 1 of 2  
 8/10/02

FORM PTO-1449 	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. <b>ASILMR-2</b>	SERIAL NO. <b>09/707,730</b>
		APPLICANT <b>Craig Hill et al.</b>	
		FILING DATE <b>November 6, 2000</b>	GROUP <b>1647</b>

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,977,307	11/1999	Friden et al.			
	5,948,384	09/1999	Filler			
	5,833,988	11/1998	Friden			
	5,767,288	06/1998	Stowell et al.			
	5,614,652	03/1997	Filler et al.			
	5,563,250	10/1996	Fitzner et al.			
	5,554,498	09/1996	Filler et al.			
	5,505,931	04/1996	Pribish			
	5,502,037	03/1996	Kondratyev			

**RECEIVED**

**AUG 19 2002**

**TECH CENTER 1600/2900**

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 97/26275	07/1997	WIPO				
	WO 97/23608	03/1997	WIPO				
	WO 97/21732	06/1997	WIPO				
	WO 95/32738	03/1997	WIPO				
	WO 95/07092	03/1995	WIPO				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

EXAMINER INITIAL	
	Binkley et al., "RNA Ligands to Human Nerve Growth Factor," <i>Nucleic Acids Research</i> vol. 23 no. 16: pp. 3198-3205 (1995).
	Fiume et al., "Galactosylated poly(L-lysine) as a Hepatotropic Carrier of 9-β-D-arabinofuranosyladenine 5'-monophosphate," <i>FEBS</i> 3810 vol. 203 no. 2: pp. 203-206 (July 1986).
	Fiume et al., "Drug Targeting in Antiviral Chemotherapy: A Chemically Stable Conjugate of 9-β-D-Arabinofuranosyl-Adenine 5'-Monophosphate with Lactosaminated Albumin Accomplishes a Selective Delivery of the Drug to Liver Cells," <i>Biochemical Pharmacology</i> vol. 35 no. 6: pp. 967-972 (1986).
	Haschke et al., "Preparation and Retrograde Axonal Transport of an Antiviral Drug/Horseradish Peroxidase Conjugate," <i>Journal of Neurochemistry</i> vol. 35 no. 6: pp. 1431-1435 (December 1980).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

